InterCure, Ltd.: New Published Study Demonstrates Over-The-Counter Device Lowers Blood Pressure in Diabetic Patients

Published: Mar 09, 2009

NEW YORK--(BUSINESS WIRE)--InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced a new study published in the peer-reviewed Journal of Human Hypertension. The advance online publication of the study is now available on the journal’s website. The study will also be published in the May issue of the journal, Volume 23, Issue 5. It demonstrates use of RESPeRATE—the only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertension—for 15 minutes a day significantly lowered blood pressure in non-insulin dependent diabetics. This study reinforces nine previous studies that validate the efficacy of the device.

Back to news